The First Postpartum Depression Drug Has Been Approved By The FDA

This is a big step.

The first drug for the treatment of postpartum depression has been approved by the U.S. Food and Drug Administration. 

About half of all mothers experience what's called the "baby blues," a mild and brief depression for a short period of time after giving birth. But 10 to 20 percent of mothers experience a more prolonged, more severe depression known as postpartum depression in the time after they have a child, according to the Illinois Department of Public Health.

The new drug, called Zulresso, is a continuous IV injection that lasts for a total of 60 hours. Reacting to the news, some health professionals have criticized the impracticality of such treatment — and the cost. Sage Therapeutics, the company behind the drug, says it will be between $20,000 and $30,000 and is going to be released in June, according to Axios

Still, the news is an important first step for mothers and the health care industry.

"We don't have any treatments that are anywhere near this effective," Jess Fiedorowicz, a psychiatrist at the University of Iowa, told The Washington Post. "So this is groundbreaking in that regard."

Cover image via karimpard / Shutterstock.


Subscribe to our newsletter and get the latest news and exclusive updates.